文献速递临床微生物质量管理与危急值

头孢洛扎-他唑巴坦药敏试验的Etest梯度扩散法多中心评估

Multicenter Evaluation of the Etest Gradient Diffusion Method for Ceftolozane-Tazobactam Susceptibility Testing of Enterobacteriaceae and Pseudomonas aeruginosa.
PubMed 文献 · J Clin Microbiol · 2018-08-27

该多中心研究评估了Etest梯度扩散法对肠杆菌科细菌和铜绿假单胞菌的头孢洛扎-他唑巴坦药敏检测性能。与肉汤微量稀释法(BMD)比较,挑战菌株中肠杆菌科基本一致率92.2–96.1%、分类一致率96.1–100.0%,铜绿假单胞菌一致率均为100%;966株临床分离株中肠杆菌科基本一致率96.9%、铜绿假单胞菌98.8%。结论认为Etest准确且可重复。

要点

  • Etest与BMD对肠杆菌科和铜绿假单胞菌的C/T药敏检测一致性高。
  • 临床分离株中未发现极重大误差,仅2株重大误差。
  • CLSI折点下临床肠杆菌科和铜绿假单胞菌非敏感率分别为8.2%和12.1%。

核心结论

  • Etest梯度扩散法对肠杆菌科细菌和铜绿假单胞菌的头孢洛扎-他唑巴坦药敏试验准确且可重复。

研究设计与样本

  • 在三个临床中心用51株肠杆菌科和39株铜绿假单胞菌挑战菌株比较Etest与BMD。
  • 在四个临床中心用966株临床分离株(793株肠杆菌科、173株铜绿假单胞菌)比较Etest与BMD。

主要发现

  • 挑战菌株中肠杆菌科基本一致率为47–49/51(92.2–96.1%),分类一致率为49–51/51(96.1–100.0%)。
  • 挑战菌株中铜绿假单胞菌在各中心的基本一致率和分类一致率均为100%。
  • 临床分离株中肠杆菌科基本一致率为96.9%,铜绿假单胞菌为98.8%;肠杆菌科各菌种分类一致率均>96%。
  • 临床分离株中未发现极重大误差,发现2个重大误差(肺炎克雷伯菌和雷氏普罗威登斯菌各1株)。
  • 按CLSI折点,BMD检测挑战菌株中47.0%肠杆菌科和46.2%铜绿假单胞菌对C/T非敏感;临床分离株中8.2%肠杆菌科和12.1%铜绿假单胞菌非敏感。

关键数值与推荐

  • CLSI折点用于判定C/T非敏感。
  • 基本一致率和分类一致率的计算基于Etest与BMD比较。

临床怎么用

  • Etest可作为肠杆菌科和铜绿假单胞菌对头孢洛扎-他唑巴坦药敏检测的可靠方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ceftolozane-tazobactam (C/T) is a novel beta-lactam-beta-lactamase inhibitor combination antibiotic approved by the U.S. Food and Drug Administration in 2014 for the treatment of complicated intra-abdominal infections (in combination with metronidazole) and complicated urinary tract infections. In this study, we evaluated the performance of the C/T Etest, a gradient diffusion method. C/T Etest was compared to broth microdilution (BMD) for 51 Enterobacteriaceae challenge isolates and 39 Pseudomonas aeruginosa challenge isolates at three clinical sites. Essential agreement (EA) between the methods ranged from 47 to 49/51 (92.2 to 96.1%) for the Enterobacteriaceae, and categorical agreement (CA) ranged from 49 to 51/51 (96.1 to 100.0%). EA and CA for P. aeruginosa were 100% at all sites. The C/T Etest was also compared to BMD for susceptibility testing on 966 clinical isolates (793 Enterobacteriaceae, including 167 Klebsiella pneumoniae and 159 Escherichia coli isolates, in addition to 173 P. aeruginosa isolates) collected at four clinical sites. EA between Etest and BMD was 96.9% for Enterobacteriaceae isolates and 98.8% for P. aeruginosa isolates. Within the Enterobacteriaceae, isolates from each species examined had >96% CA. For the clinical isolates, no very major errors were identified but two major errors were found (one for K. pneumoniae and one for Providencia rettgeri). By BMD, 47.0% of Enterobacteriaceae and 46.2% of P. aeruginosa challenge strains were nonsusceptible to C/T by CLSI breakpoint criteria; 8.2% of clinical Enterobacteriaceae isolates and 12.1% of clinical P. aeruginosa isolates were nonsusceptible to C/T by CLSI breakpoint criteria. In conclusion, Etest is accurate and reproducible for C/T susceptibility testing of Enterobacteriaceae and P. aeruginosa.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Bailey AL, Armstrong T, Dwivedi HP, et al. Multicenter Evaluation of the Etest Gradient Diffusion Method for Ceftolozane-Tazobactam Susceptibility Testing of Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol. 2018. PMID: 29976590. doi:10.1128/JCM.00717-18

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。